Calcitonin in the treatment of osteoporosis

Osteoporosis International

Volumn 7, Issue 3 SUPPL. 3, 1997, Pages

  Gennari, C ^a   Camporeale, A ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

SALCATONIN;

CLINICAL TRIAL; CONFERENCE PAPER; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; NAUSEA; OSTEOPOROSIS; PARENTERAL DRUG ADMINISTRATION; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RASH; RECTAL DRUG ADMINISTRATION; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING;

AGED; BONE DENSITY; CALCITONIN; DRUG THERAPY, COMBINATION; ESTROGENS; FEMALE; FRACTURES, SPONTANEOUS; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 0031455681     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03194364     Document Type: Article

References (50)

1. Copp DH, Cameron EC, Cheney B A, et al. Evidence for calcitonin: a new hormone from the parathyroid that lowers blood calcium. Endocrinology 1962;70:638-49.
2. Chambers TJ, Dunn CJ. Pharmacological control of osteoclastic mobility. Calcif Tissue Int 1983;35:566-79.
3. Annon. Twenty-five years of salmon calcitonin: from synthesis to therapeutic use [editorial]. Calcif Tissue Int 1995;57:405-8.
4. Reginster JYL. Calcitonins: newer routes of delivery. Osteoporos Int 1993;(Suppl 2):S3-7.
5. Buclin T, Randin JP, Jacquet AF, Azria M, Attinger M, Gomez F, Burckardt P. The effect of rectal and nasal administration of salmon calcitonin in normal subjects. Calcif Tissue Int 1987;41:252-8.
6. Gennari C, Agnusdei D, Camporeale A. Calcitonin - present and future routes of drug delivery. In: Christiansen C, Riis B, editors. Osteoporosis 1993. Aalborg, Denmark: Handelstrykkeriet Aalborg 1993:405-8.
7. Gennari C. Salmon calcitonin (Miacalcic) nasal spray in prevention and treatment of osteoporosis. Clin Rheumatol 1989;8:61-5.
8. Maclntyre I, Whitehead MI, Banks LM, Stevenson JC, Wimalawansa SJ. Calcitonin for prevention of postmenopausal bone loss. Lancet 1991;I:900-2.
9. Reginster JY, Denis D, Deroisy R, et al. Long-term (3 years) prevention of trabecular bone loss with low-dose intermittent nasal salmon calcitonin. J Bone Miner Res 1994;9:69-73.
10. Young RL, Kumar N, Goldzieher JW. Management of menopause when estrogen cannot be used. Drugs 1990;40:220-30.
11. Reginster JY. Effect of calcitonin on bone mass and fracture rates. Am J Med 1991;S1:19-22.
12. Overgaard K, Riis BJ, Christiansen C, Hansen MA. Effect of salcatonin given intranasally on early postmenopausal bone loss. BMJ 1989;299:477-9.
13. Meunier PJ, Delmas PD, Chaumet-Riffaud PD. Intranasal salmon calcitonin for prevention of postmenopausal bone loss: a placebo-controlled study in 109 women. In: Christiansen C, Overgaard K, editors. Osteoporosis 1990. Copenhagen, Osteopress, 1990:1861-7.
14. Tremollieres F, Pouilles JM, Horlait S, Guignard M, Ribot C. The role of intranasal salmon calcitonin in the prevention of vertebral and femoral neck bone loss after early menopause. In: Christiansen C, Overgaard K, editors. Osteoporosis 1990. Copenhagen: Osteopress, 1990:455-8.
15. Campodarve I, Drinkwater BL, Insogna KL, Johnston C, Lang R, Lindsay R, et al. Intranasal salmon calcitonin (INSC), 50-200 IU does not prevent bone loss in early postmenopausal women [abstract]. J Bone Miner Res 1994; 9(Suppl 1):S391.
16. Ellerington MC, Hillyard CJ, Whitcroft SJ, Marsh MS, Lees B, Banks LM, et al. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis. Calcif Tissue Int 1996;59:6-11.
17. Gennari C, Agnusdei D, Montagnani M, Gonnelli S, Civitelli R. An effective regimen of intranasal salmon calcitonin in early postmenopausal bone loss. Calcif Tissue Int 1992; 50:381-3.
18. Mazzuoli GF, Tabolli S, Bigi F, Valtorta C, Minisola S, Diacinti D, et al. Effects of salmon calcitonin on loss of bone mass induced by ovariectomy. Calcif Tissue Int 1990; 47:209-14.
19. Meschia M, Brincat M, Barbacini P, Crosignani PG, Albisetti W. A clinical trial on the effects of a combination of elcatonin (Carbicalcitonin) and conjugated estrogens on vertebral bone mass in early postmenopausal women. Calcif Tissue Int 1993;53:17-20.
20. Mazzuoli GF, Passeri M, Gennari C, Minisola S, Antonelli R, et al. Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study. Calcif Tissue Int 1986;38:3-8.
21. Gruber HE, Ivey JL, Baylink DJ, Matthews M, Nelp WB, Sisom K, Chesnut CH III. Long-term calcitonin therapy in postmenopausal osteoporosis. Metab Clin Exp 1984;33:295-303.
22. Gennari C, Chierichetti SM, Bigazzi S, et al. Comparative effects on bone mineral content of calcium and calcium plus salmon calcitonin given in two different regimens in postmenopausal osteoporosis. Curr Ther Res 1985;38:455-64.
23. Avioli LV. The osteoporotic syndrome. Orlando: Grune & Stratton, 1987:121-42.
24. Gennari C, Agnusdei D, Cepollaro C, Zacchei F, Camporeale A, Montagnani M. Effect on bone mass and bone turnover of a two-year intermittent or continuous treatment with salmon calcitonin nasal spray in postmenopausal osteoporotic patients. In: Cohn DV, Gennari C, Tashjian AH, editors. Calcium regulating hormones and bone metabolism: basic and clinical aspects. Amsterdam: Elsevier, 1992:400-6.
25. Overgaard K, Hansen MA, Nielsen V-AH, Riis BJ, Christiansen C. Discontinuous calcitonin treatment of established osteoporosis: effects of withdrawal of treatment. Am J Med 1990;89:1-6.
26. Polatti F, Zara C. Anti-osteoporotic activity of synthetic salmon calcitonin (injectable and nasal spray), and of a synthetic derivative of eel calcitonin. In: Mazzuoli GF, editor. New therapeutic perspectives: the nasal spray. Proceedings of the International Symposium on Calcitonin, Rome, 26-27 March 1988.
27. Gennari C, Agnusdei D, Gonnelli S, Civitelli R, Zacchei F, Cepollaro C. Bone turnover and bone loss in early postmenopausal women. In: Christiansen C, Overgaard K, editors. Osteoporosis 1990. Copenhagen: Osteopress, 1990:673-5.
28. Civitelli R, Gonnelli S, Zacchei F, Bigazzi S, Vattimo A, Avioli LV, Gennari C. Bone turnover in postmenopausal Osteoporosis: effect of calcitonin treatment. J Clin Invest 1988;82:1268-74.
29. Gennari C, Agnusdei D, Camporeale A. Effect of salmon calcitonin nasal spray on bone mass in patients with high turnover Osteoporosis. Osteoporos Int 1993;(Suppl 1):S208-10.
30. Overgaard K, Hansen MA, Jensen SB, Christiansen C. Effect of salcatonin given intranasally on bone mass and fracture rates in established Osteoporosis: a dose-response study. BMJ 1992;305:556-61.
31. Kanis JA, Johnell O, Gullberg B et al. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. BMJ 1992;305:1124-8.
32. Agrawal RA, Cohn S, Tessier M, Verch R, Hussain M, Zanzi I. Calcitonin treatment of Osteoporosis. In: Calcitonin 1980. Proceedings of an International Symposium. Milan, October 1980. Amsterdam: Excerpta Medica, 1981:237-46.
33. Ringe JD. Behandlung der primaren Osteoporose mit Calcium und Lachscalcitonin. Dtsch Med Wochenschr 1990;115:1176-82.
34. Peyron R, Serrurier D, Edouard C, Ghozlan R, Mayoux-Benhamou A, Meunier PJ, CIGOP. Treatment of high remodeling vertebral Osteoporosis with human calcitonin: a two-year double-blind placebo controlled trial in 93 patients. In: Christiansen C, Overgaard K, editors. Osteoporosis 1990. Copenhagen: Osteopress, 1990:1430-33.
35. Rico H, Hernandez ER, Revilla M, Gomez-Castresana F. Salmon calcitonin reduces vertebral fracture rate in postmenopausal crush fracture syndrome. Bone Miner 1992; 16:131-8.
36. Burchkardt P, Burnand B. The effect of treatment with calcitonin on vertebral fracture rate in Osteoporosis. Osteoporos Int 1993;3:24-30.
37. Minaire P, Mallet E, Levernieux J, Shoutens A, Attali G, Caulin F. Immobilization bone loss: preventive effect of calcitonin in several clinical models. In: Christiansen C, Overgaard K, editors. Osteoporosis 1987. Copenhagen: Osteopress, 1987:603-5.
38. Attali G, Levernieux J, Caulin F. Recent crush fracture syndrome. Effect of salmon calcitonin. Results of three duoble blind studies and an open study. In: Christiansen C, Overgaard K, editors. Osteoporosis 1987. Copenhagen: Osteopress, 1987:930-2.
39. Arinoviche R, Arriagada M, Jacobelli S, et al. Calcitonin in acute pain due to vertebral fractures in Osteoporosis. Rev Med Chile 1987;115:1039-43.
40. Levernieux J, Julien D, Caulin F. The effect of calcitonin on bone pain and acute resorption related to recent osteoporotic crush fractures: results of a double-blind and an open study. In: Cecchettin M, Segre G editors. Calciotropic hormones and calcium metabolism. Amsterdam: Elsevier, 1986:171-78.
41. Pun KK, Chan LWL. Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. Clin Ther 1989;11:205-9.
42. Lyritis GP, Tsakalakos N, Magiasis B, Karachalios T, Yiatzides A, Tsekoura M. Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: a double-blind placebo-controlled clinical study. Calcif Tissue Int 1991;49:369-72.
43. Gennari C, Agnusdei D, Camporeale A. Use of calcitonin in the treatment of bone pain associated with Osteoporosis. Calcif Tissue Int 1991;49(2):S9-S13.
44. Gennari C, Agnusdei D, Gonnelli S, Montagnani M, Camporeale A. Confirmation of the analgesic efficacy of Miacalcic nasal in the treatment of postmenopausal Osteoporosis. In: Peck WA editor. Prevention of postmenopausal Osteoporosis. Dream or reality? Carnforth, Lancashire: Parthenon Publishing 1990:65-74.
45. Overgaard K, Riis BJ, Christiansen C, Podenphant J, Johansen JS. Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol 1989;30:435-42.
46. Reginster JY. Effects of calcitonin on bone mass and fracture rates. Am J Med 1991;91:19S-22S.
47. Grauer A, Reiner HH, Zeigler R, Raue F. Neutralizing antibodies against calcitonin. Horm Metab Res 1993;25:486-8.
48. Grauer A, Reiner HH, Lunghall S, Lindh E, Ziegler R, Raue F. Formation of neutralizing antibodies after treatment with human calcitonin. Am J Med 1993;95:439-42.
49. Granata Q, Amato A, Salvati R, Barberis F. Activity of salmon calcitonin in senile osteoporosis. Curr Ther Res 1991;49:784-91.
50. Reginster JY, Franchimont P. Side effects of synthetic salmon calcitonin given by intranasal spray compared with intramuscular injection. Clin Exp Rheumatol 1985;3:155-7.